Similar articles

• Alpha-streptococcal septicemia in leukemic children treated with continuous or large dosage intermittent cytosine arabinoside.

  Sotiropoulos SV, Jackson MA, Woods GM, Hicks RA, Cullen J, Freeman AI. Sotiropoulos SV, et al. Pediatr Infect Dis J. 1989 Nov;8(11):755-8. doi: 10.1097/00006454-198911000-00005. Pediatr Infect Dis J. 1989. PMID: 2594450
• Respiratory insufficiency in acute leukemia following treatment with cytosine arabinoside and septicemia with streptococcus viridans.

  Dybedal I, Lamvik J. Dybedal I, et al. Eur J Haematol. 1989 Apr;42(4):405-6. Eur J Haematol. 1989. PMID: 2721663 No abstract available.
• High risk of streptococcal septicemia after high dose cytosine arabinoside treatment for acute myelogenous leukemia.

  Kern W, Kurrle E, Vanek E. Kern W, et al. Klin Wochenschr. 1987 Aug 17;65(16):773-80. doi: 10.1007/BF01743253. Klin Wochenschr. 1987. PMID: 3477669
• High-dose cytosine arabinoside for the treatment of acute myeloid leukemia. Studies of the North American Marrow Transplant Group.

  Wolff SN, Brown RA, Fay JW, Herzig GP, Herzig RH, Phillips GL. Wolff SN, et al. Leukemia. 1992 Nov;6 Suppl 4:71-4. Leukemia. 1992. PMID: 1434839 Review. No abstract available.
• High dose cytosine arabinoside in the treatment of adult acute myelogenous leukaemia.

  Nemet D, Labar B, Bogdanić V, Hauptman E, Jaksić B, Minigo H, Sertić D, Mrsić M, Pavletić Z, Kovacević J, et al. Nemet D, et al. Bone Marrow Transplant. 1989 Dec;4 Suppl 3:42-4. Bone Marrow Transplant. 1989. PMID: 2697399 Review. No abstract available.